NDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
WEGOVY (semaglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY (semaglutide) is an oral small-molecule GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar, reducing hunger and promoting satiety. This represents Novo Nordisk's oral formulation entry into the high-growth weight-loss market dominated by injectable competitors.
$0.2MPart D
LaunchGrowing
12.6 years to LOEEarly-stage launch with zero competitive pressure creates high-impact career opportunities in brand-building, market development, and team expansion across commercial and medical functions.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Started Jul 2026
164 enrolled
Muscle WastingObesity & OverweightObesity
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Started Jun 2026
150 enrolled
Pediatric ObesityMetabolic and Bariatric SurgerySemaglutide
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Started Jun 2026
3,000 enrolled
Obesity & Overweight
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Started May 2026
2,500 enrolled
ObesityType 2 Diabetes
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.